Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
TDNA ETF — T. Rowe Price Biotech ETF
T. Rowe Price Biotech ETF (TDNA)
Updated November 6, 2026.
TDNA is an ETF. Its expense ratio is 0.55%. Total return is -6.2% over the past 0.1 years, 2.6 points behind SPY at -3.6%.
T. Rowe Price Biotech ETF is an actively managed equity ETF that seeks long-term capital growth in biotechnology companies. Typical holdings 60-120 names. Expense ratio 0.55%. Began trading on Nasdaq 09/17/2026. Sibling T. Rowe Price equity ETFs distribute annually; the fund has not yet paid a distribution.
TDNA holdings and sector exposure
The top 10 holdings are 28.3% of the fund.
| Ticker | Name | Weight |
|---|---|---|
| ARGX | argenx NV ADR | 4.87% |
| KYMR | Kymera Therapeutics Inc | 4.40% |
| KOD | Kodiak Sciences Inc | 2.74% |
| NTRA | Natera Inc | 2.59% |
| INSM | Insmed Inc | 2.56% |
| UTHR | United Therapeutics Corporation | 2.41% |
| VRTX | Vertex Pharmaceuticals Inc | 2.26% |
| PCVX | Vaxcyte Inc | 2.19% |
| RVMD | Revolution Medicines Inc | 2.16% |
| MRNA | Moderna Inc | 2.15% |
To see how this fund's sectors add up across your own holdings, use True Exposure.
TDNA performance versus SPY
Total return is -6.2% over the past 0.1 years, 2.6 points behind SPY at -3.6%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -3.5% | — |
| YTD | -6.2% | — |
| Since inception 2026-09-17 · 0.1 years | -6.2% | — |
TDNA key facts
- Issuer
- T. Rowe Price
- Asset type
- ETF
- Asset class
- Equity
- Inception date
- 09/17/2026
- Expense ratio
- 0.55%
- Distribution frequency
- Annual
- Last close
- $24.72 (as of 2026-11-06)
- AUM
- $10,694,555
- Average volume
- 14,755
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) has no calculation basis on file. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: T. Rowe Price or company page; prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
TDNA risks and drawbacks
Payments are annual, so cash flow is lumpy versus a monthly fund. Total return has trailed SPY over the available window.
Who may consider TDNA — and who may not
It is a weaker fit for investors who need monthly cash flow (TDNA pays annual); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on TDNA
Frequently asked questions
Does TDNA pay monthly?
No. TDNA currently pays annual, not monthly.
What is TDNA's expense ratio?
TDNA's expense ratio is 0.55%.
When does TDNA pay a dividend?
TDNA pays annual.
How has TDNA performed?
Total return is -6.2% over the past 0.1 years, 2.6 points behind SPY at -3.6%.
More securities from T. Rowe Price.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.